Gene · 9589
Papers3,474
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,474
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| FTO-mediated the destabilization of RASGRF1 mRNA impedes thyroid cancer progression and suppresses macrophage M2 polarization. | Cell Biol Toxicol | 2025 | 40760370 | PubTator, text mining | PubMed |
| WTAP-mediated m6A modification of ARG2 mRNA Inhibits Its expression and drives prostate cancer malignant progression. | Mutat Res | 2025 | 40752461 | PubTator, text mining | PubMed |
| KIAA1429-mediated ZFPM2-AS1 m6A modification promotes the proliferation, migration and invasion of osteosarcoma cells. | Oncol Lett | 2025 | 40747381 | PubTator, text mining | PubMed |
| The role of epigenetics in pulmonary fibrosis: recent advances in mechanistic insights and therapeutic implications. | Front Mol Biosci | 2025 | 40746422 | PubTator, text mining | PubMed |
| Comprehensive Analysis of N6-Methyladenosine (m6A) RNA Methylation Regulators in Soft Tissue Leiomyosarcoma. | Lab Invest | 2025 | 40744224 | PubTator, text mining | PubMed |
| M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges. | Front Oncol | 2025 | 40740874 | PubTator, text mining | PubMed |
| Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. | Signal Transduct Target Ther | 2025 | 40739089 | PubTator, text mining | PubMed |
| The Role of PIWI-Interacting RNA in Urologic Carcinoma and Its Clinical Implications. | Cancer Rep (Hoboken) | 2025 | 40737301 | PubTator, text mining | PubMed |
| Deciphering Cuproptosis in Sepsis: Mechanisms, Consequences, and Therapeutic Opportunities. | J Inflamm Res | 2025 | 40735271 | PubTator, text mining | PubMed |
| RNA m6A modification: a key regulator in normal and malignant processes. | Cell Investig | 2025 | 40734692 | PubTator, text mining | PubMed |
| FTO-mediated MMP1 m6A modification promotes osteogenic differentiation of bone marrow mesenchymal stem cells via the ERK pathway in congenital scoliosis. | Sci Rep | 2025 | 40731128 | PubTator, text mining | PubMed |
| Participants in Transcription-Replication Conflict and Their Role in Formation and Resolution of R-Loops. | Int J Mol Sci | 2025 | 40725198 | PubTator, text mining | PubMed |
| Peptide Drug: Design and Clinical Applications. | MedComm (2020) | 2025 | 40717901 | PubTator, text mining | PubMed |
| WTAP-mediated m6A methylation of circRNA_404908 promotes esophageal squamous cell carcinoma progression. | J Biol Chem | 2025 | 40707002 | PubTator, text mining | PubMed |
| Identification and Characterization of the RNA Modifying Factors PUS7 and WTAP as Key Components for the Control of Tumor Biological Processes in Renal Cell Carcinomas. | Curr Issues Mol Biol | 2025 | 40699665 | PubTator, text mining | PubMed |
| O-GlcNAcylation of METTL3 drives hepatocellular carcinoma progression by upregulating MCM10 expression in an m6A-IGF2BP3-dependent manner. | Cell Death Dis | 2025 | 40651967 | PubTator, text mining | PubMed |
| Expression of m6A-related factors in pulmonary sarcomatoid carcinoma. | Pathol Res Pract | 2025 | 40651121 | PubTator, text mining | PubMed |
| WTAP-mediated m6A modification promotes drug sensitivity by regulating NR3C1 in prostate cancer. | Sci China Life Sci | 2025 | 40650812 | PubTator, text mining | PubMed |
| WTAP Silencing protects human aortic smooth muscle cells from angiotensin II-induced senescence, apoptosis, ferroptosis, and inflammation by regulating PCSK9. | J Bioenerg Biomembr | 2025 | 40643726 | PubTator, text mining | PubMed |
| Tanshinone IIA suppresses the proliferation and fibrosis of mesangial cell in diabetic nephropathy though WTAP-mediated m6A methylation. | Sci Rep | 2025 | 40593882 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9589/papers?page=9